Podcasts about breast medical oncology

university texas professor medicine bone approaches utilizing targeting therapies rmd md anderson cancer center reachmd oncology and hematology breast medical oncology

Play Episode Listen Later Sep 15, 2023

Host: Pavani Chalasani MD, MPH Guest: Gabriel N. Hortobagyi, MD Bone metastases are the most frequent site of metastatic spread for breast cancer, especially for the luminal subtypes, which are the most frequent types of breast cancer. Here to dive further into these therapies with Dr. Pavani Chalasani is Dr. Gabriel Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology in the Division of Cancer Medicine at the University of Texas, MD Anderson Cancer Center in Houston.

HR+ Breast Cancer Management with Dr. Margaret Gatti-Mays

Oncology Brothers

Play Episode Listen Later Apr 20, 2023 22:00

Discussing the management of Hormone Receptor Positive Breast Cancer with Dr. Margaret Gatti-Mays, Section Chief of the Breast Medical Oncology at the Ohio State University Comprehensive Cancer Center, The James Cancer Hospital & Solove Research Institute. In our discussion with Dr. Gatti-Mays we cover the treatment algorithm of the hormone receptor-positive disease following the FDA expanding the adjuvant abemaciclib approval where one doesn't need Ki-67 levels anymore, and new agents recently approved by the FDA - elacestrant, TDXD and sacituzumab providing more treatment options for our patients. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

management fda breast cancer mays gatti section chief breast medical oncology

Episode 29: Breast Cancer Answers from a Medical Oncologist

DiepCJourney Podcast

Play Episode Listen Later Mar 15, 2023 38:06

In this episode of the DiepCJourney podcast I speak with a medical oncologist. Dr. Eleanora Teplinsky has her own podcast called, INTERLUDE: Cancer Stories with Dr. Teplinsky. She is Head of Breast Medical Oncology and Clinical Assistant Professor of Medicine at The Icahn School of Medicine in Mount Sinai, NY. She has a robust and education Instagram account speaking about key topics in cancer care and survivorship. She addresses the consequences of a cancer diagnosis and the very real occurrence of patients playing the “blame game” thinking they may have caused their cancer. She addresses risk factors and how risk factors are not causal. Her favorite quote in her office and what she shares with her patients is, “Inhale the future and exhale the past. I ask her about research in alcohol consumption as it relates to breast cancer patients. Dr. Teplinsky discusses those risk factors and what we need to be aware of. She carefully explains the affects of cancer treatment and how it can vary from patient to patient. Coordination of care with your medical team to manage these side affects is important. Working with your oncologist, radiologist, surgeon, and physical therapy among others becomes important in treatment management. Dr. Teplinsky shares her sage advice on using social media for breast cancer information. She also shares her thoughts on the financial toxicity breast cancer patients can face. You can find her on LinkedIn at Eleanora Teplinsky.

head ny medicine breast cancer mount sinai oncology coordination inhale clinical assistant professor oncologists icahn school survivorship medical oncologist breast medical oncology

Myth busting with an Oncologist

The Menopause and Cancer Podcast

Play Episode Listen Later Mar 8, 2023 33:37

Welcome to our myth busting session! There are many controversial topics in the cancer space. There is much confusion and as patients, we often have many questions. Many of you tell me that you've tried to ask your oncologist about various topics but were unsatisfied with the answers you got.Does a vegan diet help with hot flushes? How shall I eat to improve my chances of survival? Is movement medicine? And does it need to be “more is better?”Does hair dye and skin care increase the risk of cancer?Do deodorants increase the risk of cancer?What about underwire bras? How much alcohol is safe to drink? Is a collagen supplement safe? What about a turkey tail mushroom supplement? The fab Dr Eleanora Teplinsky, a board-certified medical oncologist specialising in breast and gynaecological oncology is on the podcast today to talk about all these questions and I am so grateful that she has taken the time for this myth busting session. She is is the Head of Breast Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, NJ and a Clinical Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York.You can find Dr. Teplinski here:https://www.instagram.com/drteplinsky/?hl=enhttps://interludecancerstories.com/about-dr-teplinsky/About Dani:The Menopause and Cancer Podcast is hosted by Dani Binnington, menopause guide, patients advocate for people in menopause after a cancer diagnosis, and founder of the online platform Healthy Whole Me. There is lots of information out there about the menopause but hardly any if you have had a cancer diagnosis as well. Many people say to me they have no idea what their options are, who to ask for help, and that they feel really isolated in their experiences. I started this podcast because there was nothing out there when I was thrown into surgical menopause at the age of 39, which followed on from my cancer diagnosis aged 33.Through the episodes, I want to create more awareness, share information from our fabulous guest experts, doctors and other specialists in the cancer and menopause field. And of course, I will share stories from the people in our community.So that together we can work towards a better menopause experience. For all of us.More educated, better informed and less alone.Connect with Dani:Instagram @healthywholeme Facebook: @healthywholeme Join Dani's private Facebook group: https://www.facebook.com/groups/menopauseandcancerchathubFor oodles of inspiration, healthy recipes, yoga classes and all round positivity go to her website: https://www.healthywholeme.com/

new york head medicine mount sinai mythbusting clinical assistant professor oncologists icahn school paramus cancer podcast breast medical oncology dani binnington

S1 Ep65: Oncology On-the-Go Podcast: Sacituzumab Govitecan for HR+/HER2– Advanced Breast Cancer

Oncology Peer Review On-The-Go

Play Episode Listen Later Feb 20, 2023 28:34

In a Twitter Spaces edition of the Oncology On-the-Go podcast, Kevin Kalinsky, MD, MS, and Jane Meisel, MD, of Emory Winship Cancer Institute, spoke with CancerNetwork® about how the FDA approval of sacituzumab govitecan-hziy (Trodlevy) for advanced or metastatic hormone receptor–positive, HER2-negative breast cancer will impact the treatment paradigm. Kalinsky, an associate professor in the Department of Hematology and Medical Oncology and director of Breast Medical Oncology, and Meisel, an associate professor in the Department of Hematology and Medical Oncology and in the Department of Gynecology and Obstetrics, discussed data from the phase 3 TROPiCS-02 trial (NCT03901339) that led to the approval and what unmet needs still exist in the space. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

spotify ms md fda oncology obstetrics gynecology tropics hematology her2 medical oncology go podcast meisel advanced breast cancer breast medical oncology kevin kalinsky

POSITIVE Trial: Stopping Hormone Therapy for Pregnancy in Breast Cancer Patients

Cleveland Clinic Cancer Advances

Play Episode Listen Later Jan 26, 2023 17:57

Stopping hormone therapy treatment to attempt pregnancy may be an option for hormone-receptor-positive breast cancer patients. Halle Moore, MD, Director of Breast Medical Oncology and Co-Director of the Comprehensive Breast Cancer Program joins the Cancer Advances podcast to discuss her research and encouraging findings of the POSITIVE trial that was presented at the San Antonio Breast Cancer Symposium (SABCS) 2022 annual meeting.

director positive trial md pregnancy hormones stopping breast cancer co director cancer patients hormone therapy breast medical oncology

TNBC SABCS 2022 Highlights with Dr. Maryam Lustberg

Oncology Brothers

Play Episode Listen Later Dec 21, 2022 16:55

Discussing Triple Negative Breast Cancer (TNBC) from the SABCS 2022 - Practice changing studies with Dr. Maryam Lustberg, Director of Breast Cancer Center, Chief of Breast Medical Oncology, Associate Professor of Internal Medicine at Yale Cancer Center - Yale School of Medicine. CME Information link: https://integrityce.com/courses/clinical-updates-from-san-antonio-triple-negative-breast-cancer-neoadjuvant-adjuvant-immunotherapy/ Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

director practice medicine chief associate professor internal medicine tnbc breast medical oncology

Breast Cancer ESMO 2022 Highlights with Dr. Maryam Lustberg

Oncology Brothers

Play Episode Listen Later Nov 8, 2022 13:49

Discussing practice-changing Breast Cancer studies presented at the European Society of Medical Oncology 2022 with Dr. Maryam Lustberg, Director of Center of Breast Cancer, Chief of Breast Medical Oncology, Associate Professor of Internal Medicine at Yale Cancer Center - Yale School of Medicine.

director medicine chief associate professor breast cancer internal medicine european society medical oncology esmo breast medical oncology

S05 E02 - MBC 101: The HER2-Low Show

Our MBC Life

Play Episode Listen Later Oct 12, 2022 60:57

The biggest news out of the June meeting of the American Society of Clinical Oncology (ASCO) was the success of a relatively new drug called Enhertu (trastuzumab deruxtecan) in treating estrogen positive (ER+) and triple negative (TNBC) breast cancers that were also HER2 low. Results of the clinical trial presented at the meeting were so positive that in August the FDA approved the drug for patients with metastatic HER2 low breast cancer that has progressed on other treatments.Most of us likely learned our cancer's positive or negative HER2 status when we were diagnosed. But how can you find out if you're HER2 low? And what does this mean for treatment? In this episode, pathologist David G. Hicks MD, Professor and Director of IHC-ISH Laboratory Breast Subspecialty Service at the University of Rochester, and Maryam Lustberg MD, MPH, Director of the Center for Breast Cancer at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, help the Our MBC Life team understand HER2 low and what it means for treatment.Spoiler alert: In its Phase III clinical trial, Enhertu significantly extended both progression-free survival and overall survival versus standard of care chemotherapy—an outcome that earned its research team a standing ovation at ASMO. However, the drug has significant side effects, and Our MBC Life's Natalia Green shares her experience with her own treatment.ResourcesDavid G. Hicks, MD bio - www.urmc.rochester.edu/people/20643669-david-g-hicksMaryam Lustberg, MD, MPH - https://medicine.yale.edu/profile/maryam_lustberg/Newly published by Dr. Hicks: https://www.sciencedirect.com/science/article/abs/pii/S0740257022000570The official press release from ASCO re Enhertu: https://www.asco.org/about-asco/press-center/news-releases/novel-antibody-drug-conjugate-doubles-progression-free

De-Bunking Breast Cancer Myths! With Dr. Eleonora Teplinsky, Head of Breast Medical Oncology at Valley Health System and Clinical Assistant Professor of Medicine at Icahn School of Medicine at Mount Sinai

Dear Cancer, I'm Beautiful

Play Episode Listen Later Sep 7, 2022 35:48

Melissa takes a deep dive into the world of breast cancer myths with the amazing Dr. Eleonora Teplinsky. Should you avoid eating soy? Is it ok to continue exercising during chemo? What are the pros and cons of cold capping? Can you still get your nails done during treatment? Tune in to hear the answers to all of these questions and many more!

head myths valley breast cancer mount sinai health systems clinical assistant professor breast medical oncology icahn school of medicine

Highlights from the 2022 MASCC Annual Meeting, with Maryam Lustberg, MD, MPH

Cancer.Net Podcasts

Play Episode Listen Later Sep 1, 2022 9:23

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In this podcast, Dr. Maryam Lustberg discusses highlights from the Multinational Association of Supportive Care in Cancer's 2022 Annual Meeting, held June 23-25 in Toronto. Dr. Lustberg is the Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center; Chief of Breast Medical Oncology at Yale Cancer Center; Associate Professor of Medicine at Yale School of Medicine; and the 2022 President of the Multinational Association of Supportive Care in Cancer. She is also a member of the Cancer.Net Editorial Board. View Dr. Lustberg's disclosures at Cancer.Net. Dr. Lustberg: Hello, everyone. I'm Dr. Maryam Lustberg. I am chief of breast oncology at Yale Cancer Center, co-chair of Symptom Intervention Committee for Alliance Clinical Trials, and the new president of the international society of Multinational Association of Cancer Supportive Care, or MASCC. And I'm here to talk to you about updates from the meeting that happened in Toronto in June of 2022. I have no relationships to disclose relevant to the topics that I will be talking about today. And there were 3 broad themes in the meeting that I would like to highlight for you. One theme was a global focus on disparities in the delivery of cancer supportive care. So we do know that even in North America, patients with different socioeconomic backgrounds, different races, different cultural backgrounds, may not have as full access to cancer supportive care services, and that can include access to symptom management, survivorship care, palliative care. The umbrella of cancer supportive care is quite broad, and it's really focused on supporting patients and their families throughout the care continuum in a very multidisciplinary, holistic way. And so what we're finding, unfortunately, similar to cancer treatment, access to the best supportive care in cancer can also face certain disparities in the U.S. and North America. And this is something that we talked quite a bit about in the meeting in terms of recognizing this as well as finding solutions for it. And similarly, globally, we know that access to symptom management strategies, access to palliative care, access to oncology rehab, all of these can be quite restricted in different regions of the world. So the meeting in Toronto was really a call to action to recognize this as a pressing issue for our global community. And we will be forming several task forces to really look towards solutions. And so we look forward in terms of looking at low-hanging fruit interventions that we can both provide in North America as well as globally so that really patients and families could have access to such an important part of cancer care. The second theme of the meeting focused on digital technologies as well as the impact of COVID-19 on the delivery of cancer supportive care. We know that the pandemic certainly shook the world, and it also impacted patients' access to supportive care services. These were often the services that were put on hold, understandably, during the resource-lean times and restricted access to services during the pandemic. So this was something that we absolutely recognize that this happened. It impacted many patients and families, but we also, as a community, really came together to come up with innovative solutions. And one of these innovative solutions, what people have called maybe the silver lining in what happened during COVID, is that there was an increase in telehealth services, including telehealth care delivery of some of these supportive care services. So a lot of the meeting focused on how this was implemented, what access may have looked like. There's certainly disparities even here in terms of access to telehealth services. And also patient preferences and caregiver preferences also plays a great role here, where some patients really find telehealth to be a really comfortable solution for them. They don't have to leave their home, find parking, but others may find it less personal. So really, if we're thinking about personalizing cancer supportive care, I think there was a lot of discussion about making sure that we kind of understand which clinical situations may benefit from telehealth care delivery, which situations may do better with face-to-face, and ultimately to really involve patients and families in that decision and to make sure that we're engaging and not dictating policies without their full engagement. So this is something that we absolutely care deeply about. The third theme focused on burnout. There was a lot of focus on clinician burnout, which we know was also something that was a tremendous issue during the pandemic due to workforce shortage across all health care disciplines. People have talked quite a bit about the great resignation, where many health care workers as well as people in other sectors actually resigned or could not work in the conditions that the pandemic necessitated. So there was a lot of focus on recognizing burnout in clinicians because that directly impacts how well we can take care of patients. So recognizing it and thinking about proactive solutions, including there was a wonderful speaker, Dr. Benjamin Corn, who has done quite a bit of research on hopefulness and really feeling hope, whether you're a caregiver, whether you're a clinician or a patient, was found to be a key measure or predictor of burnout. And this is not meant to minimize system issues or anything like that. But I think there was a lot of focus on self-management and self-efficacy, kind of recognizing burnout and trying to foster things that we can do ourselves to keep ourselves healthy mentally, emotionally, and spiritually so that we can continue to function in the health care setting and take the best care of our patients, which is ultimately our goal as an entire scientific oncologic community is to be more present, to be more engaged, to deliver the best evidence care whether it be in the realm of cancer treatments or cancer supportive care, I do feel it's all part of that full package. Thank you so much for listening to this podcast. ASCO: Thank you, Dr. Lustberg. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Does Detecting Metastatic Disease Early Make a Difference? - Professor Prue Francis

Breast Cancer Trials

Play Episode Listen Later Aug 23, 2022 5:21

Professor Prue Francis is a Medical Oncologist and the Clinical Head of Breast Medical Oncology at the Perter McCallum Cancer Centre. Professor Francis is researching into Metastatic breast cancer, asking the question: Does Detecting Metastatic Disease Early Make a Difference? We asked Professor Francis to explain her research on this topic.

professor disease make a difference detecting metastatic medical oncologist breast medical oncology

Dr. Sara Hurvitz | Breast Medical Oncology | Current Approach to Metastatic Triple Negative & HER2+ Breast Cancer, CDK4/6 Inhibitors & T-DXD (Enhertu)

PrecisCa Oncology Podcast : Precision Cancer Insights

Play Episode Listen Later Jun 9, 2022 24:40

On this episode, PrecisCa speaks with Dr. Sara Hurvitz, medical oncologist & the Director of Breast Oncology at the David Geffen School of Medicine at UCLA. Dr. Hurvitz answers the following: What are the biggest advances in breast cancer in 2021? What is your current approach to metastatic triple negative breast cancer? How do you choose between CDK4/6 inhibitors in both the curative and metastatic settings? How do you treat metastatic HER2 positive breast cancer with organ dysfunction through various lines of therapy? Did we learn any new information about T-DXD (Enhertu) in 2021? How do you envision the future development of T-DXD (Enhertu)? Sara A Hurvitz, MD, is Professor of Medicine at the University of California, Los Angeles (UCLA); co-director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA; and Director of Breast Oncology. Dr. Hurvitz received board-certification in internal medicine, hematology, and medical oncology. Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.

director university california professor medicine current md negative ucla triple breast cancer medical director inhibitors metastatic her2 david geffen school los angeles ucla cdk4 breast oncology enhertu breast medical oncology clinical research unit sara hurvitz

Combatting Breast Cancer with Chemoprevention

The "Don't Call it a Journey" Podcast

Play Episode Listen Later May 5, 2022

Host: Jacob Sands, MD Guest: Marie Wood, MD Can our breast cancer patients benefit from chemoprevention? Joining Dr. Jacob Sands to share treatment options for chemoprevention and which patients may benefit the most is Dr. Marie Wood, the Director of Breast Medical Oncology and Director of the Cancer Clinical Trials Office at the University of Colorado Anschutz Medical Center.

director university breast cancer combatting rmd reachmd oncology and hematology chemoprevention breast medical oncology marie wood

Dr. Eleonora Teplinksy on Connecting with Patients, Exciting New Research, and the Importance of Navigating Misinformation and Living a Healthy Lifestyle

Play Episode Listen Later Apr 4, 2022 46:08

“You were created to do good work. Work that empowers and inspires, liberates and transforms, restores and softens. Yes, work can be hard - as it was meant to be. The verb itself calls us into action, rejecting passivity and demanding sustained effort…But this work…It changes things. So when you're feeling weary, or hopeless, or spent, remind yourself that the darkness is being flooded by marvelous light. Yes, this is work, and it is good” -Danielle Coke Today is an episode that I am incredibly excited for! Dr. Eleonora Teplinksy has been someone I have followed on instagram for a while now – she is the head of Breast Medical Oncology at a hospital in New Jersey, and she uses her platform to share incredibly helpful information and resources. I am so happy that she agreed to come on the podcast today to share her incredible insights and I hope that you all enjoy learning from her! To listen to Dr. Teplinksy's podcast, click here! https://podcasts.apple.com/us/podcast/interlude/id1451816690 To follow Dr. Teplinksy on Instagram, click here! Eleonora Teplinsky, MD (@drteplinsky) • Instagram photos and videos Other helpful links: Eleonora Teplinsky, MD | Linktree

work navigating new jersey connecting patients md misinformation healthy lifestyle new research exciting new breast medical oncology

#167 PhenoTips: Future of Cancer Genetics

DNA Today: A Genetics Podcast

Play Episode Listen Later Jan 14, 2022 77:00

DNA Today's host Kira Dineen is also the host of the PhenoTips Speaker Series. This monthly live webinar focuses on relevant genetics topics by featuring discussions with thought leaders and experts in genomic medicine. In this podcast episode we are sharing an installment of the PhenoTips Speaker Series, “The Future of Cancer Genetics”.Thanks to advancements in genome sequencing, physicians are equipped with improved knowledge on the causes of cancer, as well as alternative treatment options for specific cancers. Despite this growing wealth of cancer genomics data, experts remain unclear on how to translate cancer genetics knowledge into realizing precision medicine. To prepare practitioners for the future of cancer genetics, PhenoTips invited Dr. Banu Arun and Dr. Mark Robson to share their insights.Dr. Arun is a Professor in the Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetic Program, and Section Chief of Breast Genetics, Prevention, and Screening at the University of Texas MD Anderson Cancer Center. Hailed by Forbes as one of the top 30 Breast Medical Oncologists in the United States, she has received the FASCO award recognition in 2020 from the American Society of Clinical Oncology (ASCO) and the ASCO-American Cancer Society 2021 Award. Dr. Arun has more than 200 peer-reviewed publications with research focusing on identifying risk biomarkers for breast cancer, and characterizing risk factors in high-risk women with hereditary gene mutations as well as assessing their breast cancer biology. In addition she has reviewed for prestigious journals, such as BMJ, JCO, Cancer, Cancer Prevention and Epidemiology, and served in several committees including her current position as the Co-Chair for the SWOG Prevention and Epidemiology Committee.Dr. Robson is the Chief of the Breast Medicine Service in the Department of Medicine at Memorial Hospital, New York, Attending Physician on Breast Medicine and Clinical Genetic Services, and a Member of the Memorial Sloan Kettering Cancer Center. He is an associate editor for the Journal of the National Cancer Institute and a Fellow of the American Society of Clinical Oncology (ASCO), as well as a past chair of the ASCO Ethics Committee. His clinical research is on the optimal application of germline information to the management of cancer patients. He has been a lead investigator for trials of PARP inhibitors in patients with BRCA mutation–associated breast cancer and is currently developing new models for the acquisition of germline information, including "mainstreaming" through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. In addition, he is investigating the use of polygenic risk scores in facilitating decision-making among women with or without an inherited predisposition.In this webinar moderated by Kira Dineen, Dr. Arun and Dr. Robson will illuminate the future of cancer genetics by discussing:The latest technological advancements in cancer genetics.Barriers in the specialty and methods to overcome them.Strategies to prepare practitioners for the future of cancer genetic care.Hope to see you live for the next installment of Phenotips Speaker Series on January 18th about ending the diagnostic odyssey! PhenoTips' Chief Operating Officer and VP of Scientific & Medical Affairs, Dr. Pawel Buczkowicz, will be speaking with Dr. Ana Cohen, Clinical/Research Assistant Director of the Molecular Genetics Laboratory at Children's Mercy's Center for Pediatric Genomic Medicine. Register here for the live event on January 18th at 11am-12pmEST. Stay tuned for the next new episode of DNA Today on January 21st, 2022 with Allelica's Giordano Bottà to discuss polygenic risk scores! New episodes are released on Fridays. In the meantime, you can binge over 165 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com.Do you want to connect with other people who have the same genetic variant as you? You should check out “Connect My Variant”, it's an online resource that allows you to do just that. “Connect My Variant” also provides different avenues of informing your family of possible inherited risk of disease. This includes helping find where your variant came from and finding distant cousins that may also be at risk. The University of Washington has supported the “Connect My Variant” project in an effort to help patients and families understand where their unique genetic variants come from. Check out it at ConnectMyVariant.com. (SPONSORED)Did you know that most cancer samples cannot be subjected to some of the most common cytogenetic analyses due to their storage in formalin and other intractable storage conditions? Don't let difficult sample types and convoluted assay cascades get in the way of your research! Phase Genomics has developed a brand new Next Generation Cytogenomics platform to advance discovery in reproductive genetics and precision oncology. A single assay has the ability to do comprehensive testing for chromosomal abnormalities in fresh, frozen, AND even paraffin-embedded FFPE samples. Learn more about Phase Genomics' incredible new platform in cytogenomics by visiting PhaseGenomics.com. You can also hear our in depth interview with them on episode 169 of DNA Today which will be released on January 28th. (SPONSORED). PerkinElmer Genomics is a global leader in genetic testing focusing on rare diseases, inherited disorders, newborn screening, and hereditary cancer. Testing services support the full continuum of care from preconception and prenatal to neonatal, pediatric, and adult. Testing options include sequencing for targeted genes, multiple genes, the whole exome or genome, and copy number variations. Using a simple saliva or blood sample, PerkinElmer Genomics answers complex genetic questions that can proactively inform patient care and end the diagnostic odyssey for families. Learn more at PerkinElmerGenomics.com. (SPONSORED)Are you a genetic counselor or genetic counseling student? Join me in participating in a research study surrounding education on gender-affirming care in genetic counseling. This study is from the University of Michigan Genetic Counseling Program. It requires a pre and post test survey along with an online 2-3 hour educational tool. I just got access to the modules and am looking forward to learning this week! And here's a bonus: you are entered to win one of 10 $50 gift cards! Complete the survey here . (SPONSORED).

Survivorship Care for Breast Cancer Patients: Exploring the Role of the Primary Care Physician

director chief md breast cancer cancer patients rmd survivorship primary care physicians reachmd yale cancer center general medicine and primary care oncology and hematology host jennifer caudle breast medical oncology

Play Episode Listen Later Jan 3, 2022

Host: Jennifer Caudle, DO Guest: Maryam Lustberg, MD, MPH Developing a coordinated survivorship care plan between oncologists and primary care physicians is a top priority for cancer patients. To better understand what goes into this, Dr. Jennifer Caudle is joined by Dr. Maryam Lustberg, Director of The Breast Cancer Center at the Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, to discuss the role of the primary care physician in survivorship care for breast cancer patients.

Cardiac Rehabilitation: Key Considerations for Breast Cancer Survivors

Heart Matters

Play Episode Listen Later Dec 17, 2021

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Maryam Lustberg, MD, MPH Can cardiac rehabilitation programs play a role in the management of breast cancer survivors? Dr. Maryam Lustberg, Chief of Breast Medical Oncology and the Director of The Breast Cancer Center at Smilow Yale Cancer Center, shares the common risk factors between cardiovascular disease and cancer and why these types of programs are beneficial to patient care.

director chief md cardiology breast cancer survivors rmd heart matters key considerations faha cardiac rehabilitation reachmd oncology and hematology breast medical oncology alan s brown host alan s

Finetuning Breast Cancer Risk Assessment & Reduction: A Session from SABCS 2021

university professor executive director breast cancer reduction risk assessment fine tuning preventive medicine cancer risk rmd risk reduction texas md anderson cancer center cancer genetics reachmd oncology and hematology breast medical oncology

Play Episode Listen Later Nov 30, 2021

Guest: Banu Arun, MD Here to give highlights from the “Finetuning Risk Assessment and Risk Reduction” session at the 2021 San Antonio Breast Cancer Symposium (SABCS) is Dr. Banu Arun, Professor of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center and Executive Director of Cancer Genetics for the MD Anderson Cancer Networks.

Metastatic Breast Cancer: Accessing the Best Treatment For YOU

Empowered!

Play Episode Listen Later May 26, 2021 39:19

How could genetic testing results impact your metastatic breast cancer treatment options? In this podcast, Dr. Julie Gralow will discuss essential testing, the latest targeted therapies and emerging breast cancer research.About the Guest:Dr. Julie Gralow is the Jill Bennett Endowed Professor of Breast Medical Oncology at the University of Washington, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance. More about this expert: https://www.seattlecca.org/providers/julie-r-gralow.

university washington treatments accessing metastatic breast cancer fred hutchinson cancer research center breast medical oncology

Finding Your Own Way with Julie Gralow, MD

Oncology Overdrive

Play Episode Listen Later Nov 19, 2020 46:04

Julie Gralow, MD, is a well-respected and internationally renowned breast oncologist. In this episode, Gralow discusses her journey in oncology, the ASCO Global Oncology Task Force and the importance of finding your own way in medicine. Intro :14 About Gralow :27 The interview 1:49 What has been your journey to become the very well-respected internationally renowned breast oncologist you are today? 2:21 How did you find yourself in that aspect of the field and also marry in your interest in mobile oncology? 4:31 Were there times where you faced barriers you weren’t going to be able to overcome? 13:13 How did you feel and what did you think when you led the ASCO Global Oncology Task Force? 16:15 What are some of the high points that came out of the ASCO Global Oncology Task Force report? 19:20 Did you focus on how the COVID-19 pandemic affected oncology management in this task force or in any of your global oncology work? 26:30 Did you find that social media was a useful tool throughout the last 9-10 months navigating the pandemic? 30:11 Realizing the benefits of social media as a medical professional and avoiding “doom scrolling” 34:00 Do you have one pearl for the audience? 41:47 How to find Julie Gralow 43:11 Where does Gralow see her future career going? 44:22 Julie Gralow, MD is the Jill Bennett Endowed professor of Breast Medical Oncology and professor of global health at the University of Washington School of Medicine, professor in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, and director of Breast Medical Oncology at the Seattle Cancer Care Alliance. We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Julie Gralow can be reached on Twitter @jrgralow and by email at pink@uw.edu. Follow us on Twitter @HemOncToday @ShikhaJainMD. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Gralow reports no relevant financial disclosures.

covid-19 university medicine md jain washington school fred hutchinson cancer research center finding your own way breast medical oncology clinical research division

Breast Cancer Screening and Treatment During the Coronavirus Pandemic

Butts & Guts: A Cleveland Clinic Digestive Health Podcast

Play Episode Listen Later Oct 13, 2020 14:30

As one of most common cancers among women in the United States, it's vital to receive annual breast cancer screenings and necessary treatment, even during a global pandemic. Halle Moore, MD, Director of Breast Medical Oncology and Co-Director of the Comprehensive Breast Cancer Program at Cleveland Clinic Cancer Center, joins Butts & Guts to discuss how Cleveland Clinic has adapted its breast cancer program to maintain care for patients during COVID-19.

covid-19 united states director md treatments screenings co director guts coronavirus pandemic butts cleveland clinic breast cancer screening breast medical oncology

Insights from Cleveland Clinic’s Breast Cancer Survivorship Program

Cleveland Clinic Cancer Advances

Play Episode Listen Later Oct 8, 2020 17:36

Upon completing cancer treatment, a patient’s journey is truly just beginning. Halle Moore, MD, Director of Breast Medical Oncology and Co-Director of the Comprehensive Breast Cancer Program discusses Cleveland Clinic’s breast cancer survivorship program. Listen as Dr. Moore shares her learnings from more than a decade of research to improve the quality of life for cancer survivors.

director md breast cancer co director cleveland clinic cancer survivorship breast medical oncology

Dr Julie Gralow Comments on Breast Cancer Management in Seattle during the COVID-19 Pandemic

Oncology Today with Dr Neil Love

Play Episode Listen Later May 3, 2020 25:13

Dr Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance, reviews how telemedicine and the screening, diagnosis and treatment of breast cancer have rapidly adapted based on resource limitations and risk factors related to COVID-19. Additional Resources * Soran A et al. Breast cancer diagnosis, and follow-up during COVID-19 pandemic. Eur J Health 2020;16(2):86-8. Abstract (https://pubmed.ncbi.nlm.nih.gov/32285027/) * American College of Surgeons. COVID-19 guidelines for triage of breast cancer patients. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer * Falandry C et al. Challenges with the management of older patients with cancer during the COVID-19 pandemic. J Geriatri Oncol 2020;[Online ahead of print]. Abstract (https://www.sciencedirect.com/science/article/pii/S1879406820301533)

2019 ASCO Annual Meeting Research Round Up: Breast Cancer, Head and Neck Cancer, and Cancer-Related Nausea and Vomiting

Cancer.Net Podcasts

Play Episode Listen Later Jun 25, 2019 24:32

ASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world’s leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. The 2019 ASCO Annual Meeting, held May 31 to June 4, brought together physicians, researchers, patient advocates, and other health care professionals from around the world to present and discuss the latest research in cancer treatment and patient care. In the annual Research Round Up podcast series, Cancer.Net Associate Editors share their thoughts on the most exciting scientific research to come out of this year’s ASCO Annual Meeting and what it means for patients. First, Dr. Lynn Henry will discuss 3 studies that explored new treatment options for women with breast cancer, including a study on immunotherapy for triple-negative breast cancer and 2 studies on treatment for hormone receptor positive, HER2-negative breast cancer. She also discusses research on the effects of a low-fat diet in women diagnosed with breast cancer, and a study on whether pregnancy after breast cancer increased the risk of recurrence. Dr. Henry is an Associate Professor and Interim Division Chief of Oncology in the Department of Medicine at the University of Utah and Director of Breast Medical Oncology at the Huntsman Cancer Institute. She is also the Cancer.Net Associate Editor for Breast Cancer. Dr. Henry: Hi. My name is Dr. Lynn Henry. I'm a medical oncologist who specializes in treating breast cancer at the University of Utah. Today, I'm going to discuss research on breast cancer that was presented at the 2019 ASCO Annual Meeting in Chicago. In particular, I'm going to focus on the results of some clinical trials that directly impact how oncologists treat patients with breast cancer. First, I'm going to give just a very brief overview of the types of breast cancer and then talk about some research that was presented on triple-negative and hormone-receptor-positive breast cancer. Then I'm going to briefly review findings related to diet and breast cancer as well as pregnancy after breast cancer in women with BRCA mutations. As a quick reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone-receptor positive or estrogen-receptor positive, and those are stimulated to grow by estrogen. We treat those cancers with anti-estrogen treatments or anti-hormone treatments to block estrogen or lower the estrogen level in the body. Other breast cancers are called HER2-positive. These are often more aggressive cancers. But because they have extra copies of HER2, they often respond to treatments that block HER2. And finally, there are breast cancers that don't have hormone receptors or HER2, and these are called triple-negative breast cancer. So first, I'm going to focus on this type, triple-negative breast cancer. Until recently, most of the time, we treated triple-negative breast cancer with chemotherapy because we hadn't found other drugs that worked very well. There's a new type of drug, however, called immunotherapy that tries to use a patient's immune system to help fight the breast cancer. Early in 2019, the FDA approved a new treatment for triple-negative breast cancer that is a combination of a chemotherapy called Abraxane and a new immune drug called atezolizumab or Tecentriq. The combination increased the length of time until cancer progressed or grew. Overall, the treatment was fairly well tolerated. But we did learn that in order for the treatment to work, the cells surrounding the cancer have to have at least a small amount of a very specific protein called PD-L1. So at this recent ASCO meeting, we heard an update about this treatment. In the trial, the patients whose cancers had the PD-L1 protein and who got the combination treatment lived 7 months longer than those who got just the chemotherapy, which was an increase from 18 months to just over 2 years. This is an important first step towards finding a better treatment for this difficult type of triple-negative breast cancer. And this treatment is currently available to patients. Additional clinical trials are going on now to try to find even better combinations of chemotherapy and immune therapies to treat this type of cancer. So next, I'm going to talk about hormone-receptor-positive breast cancer. There were two trials of this type of cancer that had important results presented at the ASCO meeting. First, I'll focus on the treatment of early-stage node-negative breast cancer that is hormone-receptor positive and HER2 negative. The Oncotype DX test is a test we commonly run on tumors of this type to help determine whether treatment with chemotherapy is likely to be helpful. For this test, if your tumor has a score over 25, then chemotherapy is generally recommended in addition to anti-hormone therapy. If you have a score under 11, then chemotherapy is not recommended and a patient should receive only anti-hormone therapy. But for those with scores between 11 and 25, it was unclear how beneficial it was to receive chemotherapy. Last year, the results of the TAILORx trial were reported. And that showed that for women over the age of 50, if their tumor had a score between 11 and 25, they were not likely to get benefit from chemotherapy. However, it turned out it was a bit more complicated for women aged 50 and under. For those with scores between 11 and 15, chemotherapy was not likely to be beneficial. However, for those who score 16 to 25, chemotherapy might be beneficial. So we got some answers but not everything. At this recent ASCO meeting, additional information was reported to help guide treatment decision making for this middle group of women aged 50 and under. So for women whose scores were at the higher end, 21 to 25, chemotherapy was found to be likely to be beneficial. However, in that middle group, the 16 to 20 group, chemotherapy might be beneficial but generally only for women with higher risk cancers, meaning larger cancers or higher grade. This information is helpful because it provides more information for oncologists and for patients when they are discussing whether or not chemotherapy should be included as part of their treatment. So switching gears a little, still staying with premenopausal women and hormone-receptor-positive HER2-negative cancer, but now thinking about metastatic breast cancer, so cancer that has spread. We now have additional information about treatment with an anti-hormone therapy plus an additional drug called the CDK4/6 inhibitor. We've routinely been recommending this treatment combination because it leads to a longer time before the cancer progresses. But until now, we didn't know if it actually allows women with this type of cancer to live longer. The results of the MONALEESA-7 trial, which looked at the combination of an anti-hormone therapy plus the drug called ribociclib, showed that women who received the combination instead of anti-hormone therapy alone live almost 30% longer. So looking at women 3 and a half years after they started treatment, just over 70% of the women who were treated with ribociclib plus anti-hormone therapy were alive compared to just under half of women treated with anti-hormone therapy alone. So these results reinforce that this is an excellent first approach to treatment of premenopausal women who have newly diagnosed, hormone-receptor-positive HER2-negative metastatic breast cancer. So in addition to studies looking at these specific types of breast cancer, there were 2 other interesting studies that were applicable to breast cancer more generally. So there was a large study that was reported that looked at whether having a low-fat diet reduced the likelihood of developing triple-negative breast cancer. So in this study, postmenopausal without cancer were randomized to either a low-fat diet or their usual diet and followed for many, many years. Over time, some of these women developed breast cancer with no difference between those who followed the low-fat diet or the regular diet. However, in this new report, they looked specifically at the women who developed breast cancer who were enrolled in this trial. Fewer women died from their breast cancer if they ate the low-fat diet, especially if they had preexisting high cholesterol, diabetes, and obesity. These findings suggest that having a low-fat diet may actually reduce the risk of dying overall and also specifically from breast cancer. Now, these need to be validated, and we don't quite understand why this would be the case. But in general, it seems like having a low-fat diet, avoiding high cholesterol, diabetes, and obesity is a good thing. And then finally, 1 question that comes up often is whether it is safe to have a baby after the diagnosis of breast cancer. This is especially concerning for patients who have a mutation in genes called BRCA1 or BRCA2 since those mutations greatly increase their risk of developing both breast and ovarian cancer and also leads to the diagnosis of breast cancer at an early age. In addition, patients with these mutations are often recommended to have their ovaries removed at a young age. So in this study, patients who became pregnant did so about 4 and a half years after they were diagnosed with breast cancer. There was no apparent increase in miscarriage, preterm birth, or birth defects compared to what would be expected in women without cancer. And in the patients, there was no increase in the risk of breast cancer recurrence compared to those who did not become pregnant. And in fact, those who became pregnant were slightly less likely to have their cancer return, especially those who had mutations in BRCA1. So while there are some limitations to the study, the findings are reassuring that there does not appear to be an increase in risk of breast cancer returning in these patients with BRCA mutations who become pregnant after breast cancer diagnosis. So overall, as you can see, there's a lot of exciting research going on across all the different subsets of breast cancer. The results of many important clinical trials were reported at the recent ASCO meeting, and there are many more trials ongoing that will hopefully result in the approval of multiple new effective treatments for breast cancer. In addition, there's research going on examining the impact of treatment on patients with breast cancer and trying to improve the lives of those living with breast cancer. Clinical trials are critical for the development of these new treatments. Well, that's it for this quick summary of this important research from ASCO 2019. Overall, we continue on a fast track in breast cancer, with many new and exciting therapies being actively studied and research helping support our patients do better than ever before. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you very much. ASCO: Thank you, Dr. Henry. Next, Dr. Ezra Cohen will discuss several studies that looked at using immunotherapy and targeted therapy to treat different types of head and neck cancer. Dr. Cohen is Associate Director of Translational Science and leads the Solid Tumor Therapeutics research program at Moores Cancer Center at UC San Diego Health. He is the Cancer.Net Associate Editor for Head and Neck Cancer. Dr. Cohen: Hi. I'm Dr. Ezra Cohen from UC San Diego Moores Cancer Center. Today, I'm going to talk about research on head and neck cancer that was presented at the 2019 ASCO Annual Meeting. I think the most impactful presentation at the meeting was a follow-up on the KEYNOTE-048 study, which implemented the drug pembrolizumab, an anti-PD-1 antibody in first-line recurrent metastatic head and neck cancer. These were patients who were treated with curative intent or presented with metastatic disease, and either way, either had recurrence or eventually developed metastases. The first-line standard of care for these patients used to be the so-called extreme regimen, which involved platinum, 5-FU, and cetuximab. This was validated in an earlier phase III study that was conducted about 10 years ago and was the approved first-line regimen for these patients. In KEYNOTE-048, this extreme regimen was tested against either pembrolizumab alone or pembrolizumab, platinum, and 5-FU, in other words, substituting cetuximab for pembrolizumab in one of the experimental arms. We'd initially seen the interim analysis data at last year's ESMO meeting, but this year, we have the final analysis presented at ASCO. And what we saw was that both experimental arms actually achieved an improvement in overall survival compared to the extreme regimen. Interestingly, for pembrolizumab alone, this occurred in patients whose tumors expressed some level of PD-L1. That was evaluated by something called the composite score and takes into account both stromal and tumor cell staining of PD-L1. In fact, even at a very low level—that is CPS greater than or equal to 1—pembrolizumab monotherapy was superior to the extreme regimen with respect to overall survival. For all patients, the regimen of pembrolizumab plus chemotherapy was superior to the extreme regimen irrespective of PD-L1 staining. What we saw at this year's ASCO meeting was that, in fact, first, the higher the expression of PD-L1, the greater the benefit one derived from pembrolizumab either as monotherapy or in combination with chemotherapy. And in patients who had higher levels of PD-L1 and received both pembrolizumab and chemotherapy, the overall survival was quite remarkable with a hazard ratio of just higher than 0.6. In fact, we now have FDA approval in the United States for pembrolizumab monotherapy with tumors that have some expression level of PD-L1—that is CPS greater than or equal to one—or for all comers in patients who either the CPS status is unknown or patients whose tumors don't express PD-L1. Beyond KEYNOTE-048, we saw interesting data in first-line recurrent metastatic using a regimen of taxane, platinum, and 5-FU compared to the same extreme regimen that we just mentioned. That regimen turned out to be much better tolerated with fewer adverse events but with no improvement in overall survival, giving us a regimen that we could substitute for the extreme regimen if one wanted to, realizing that it does not involve immunotherapy, and for some patients, this may still be an appropriate treatment. Beyond the first-line recurrent metastatic studies, we saw a few interesting trials looking at targeted therapy in head and neck cancer but specific subsets. The first was in patients whose tumors expressed HER2 at very high levels—that is HER2 amplified—and had salivary ductal carcinoma. We've known that a proportion of salivary ductal carcinoma patients' tumors amplify this gene, HER2, similar to breast cancer and some other malignancies and that trastuzumab may, in fact, be effective. Well, in this study conducted by the Memorial Sloan Kettering Group, an antibody-drug conjugate trastuzumab emtansine was employed as a single agent in these patients whose, again, tumors amplified HER2. And what they saw was a remarkable 90% response rate. Now, this was only in 10 patients, so the study is small, but I think it's safe to say that this drug appears to be quite effective in patients with HER2-amplified salivary ductal carcinoma. Along those lines, in the subset of thyroid cancer patients whose tumors either mutate or have a RET fusion, the gene RET, there appeared to be very high efficacy for a novel agent that targets the RET oncogene. This was in both patients with medullary thyroid cancers that often have a RET mutation or in papillary thyroid cancers whose tumors often have a fusion of the same RET gene. Again, underscoring the idea that if we can target a driver even in a relatively small subset of patients, the benefit may be quite large. Along those lines, we had seen prior data for track inhibitors in patients who have in track fusions. And again, this applies to subsets of head and neck cancer patients that have either salivary gland cancers or thyroid cancers. Lastly, we continue to see emerging promising data of combinations with immunotherapy, and 2 highlights from ASCO were pembrolizumab with cetuximab showing a response rate of over 40% in a small group of patients and pembrolizumab with a TLR9 agonist called SD-101 showing about a 30% response rate. Of course, these data are very early and uncontrolled, and so we have to follow these stories further along to see if, indeed, these early signs of efficacy turn out to validate. But the idea that further combinations of immunotherapies eventually making their way to larger studies and hopefully approval is now well enforced in head and neck cancer. Thank you very much for your attention and hope you enjoyed the ASCO 2019 Annual Meeting. ASCO: Thank you Dr. Cohen. Next, Dr. Charles Loprinzi will discuss new research on ways to prevent or treat nausea and vomiting caused by cancer treatment. Dr. Loprinzi is a medical oncologist and the Regis Professor of Breast Cancer Research at the Mayo Clinic. He is also the Cancer.Net Associate Editor for Psychosocial Oncology. Dr. Loprinzi: Hello, I'm Charles Loprinzi, Regis Professor of Breast Cancer Research at Mayo Clinic. I'm going to be talking today about chemotherapy-induced nausea and vomiting. Now, chemotherapy can cause a lot of nausea and vomiting. That's well known, for years and years, by many people. It's not all types of chemotherapy, but some chemotherapy drugs cause a lot of nausea and vomiting, and others cause little to none. It's not as big a problem now as it was decades ago when we didn't have good drugs to try to prevent nausea and vomiting. Many drugs over the time have been developed for trying to prevent this nausea and vomiting problem. Examples of the drugs that cause a lot of nausea and vomiting are Cisplatinum, and Adriamycin and cyclophosphamide is a combination that is oftentimes used for patients with breast cancer. So in the past, we have developed many, many drugs for this. Three of the drugs that have commonly been used for the last many, many years for treatment or prevention of nausea and vomiting associated with chemotherapy are corticosteroid medications like Dexamethasone. It's quite cheap. It's got some side effects, but relatively cheap. Then there's a group called 5-HT3 receptor antagonists. I didn't make up that name, but that's the long name for it. They're relatively expensive, some more expensive than other ones. And then there's another group called NK1 receptor antagonists, and they can be quite expensive, sometimes being hundreds of dollars for each dose that's given to try to prevent nausea and vomiting related to chemotherapy. So a couple years ago, 2016, there was a report in the New England Journal of Medicine, which is a prominent journal for us in the business, that looked at a drug called olanzapine. It's a relatively cheap drug. It's a drug that was developed for psychosis-type problems, given for long term in those patients. But it had been noted that if it's given for just a few days, it seems to markedly improve or decrease the instance of nausea and vomiting, or if people were having nausea and vomiting, it appears actually to help and reverse that particular problem. So this trial looked at 10 milligrams of this drug for 4 days, given before chemotherapy, and then for 3 more days after that. Patients who were on this study got the 3 drugs that I talked about before with the olanzapine or with the placebo. And it noted that it improved things by quite a bit. The patients who had what we call a complete response, which means no vomiting and no need to take extra medications because of nausea and vomiting, improved from 41% of the patients who were on the placebo, to 64% who were on the olanzapine, a 23% improvement. And if we looked at a different endpoint there, the number of patients who had no nausea during the five days after chemotherapy, it was 22% in the group that got the placebo and improved to 37% in the group that didn't. So it was a good result in that area. One of the problems with this drug is that it can cause some sedation, cause some drowsiness for some patients. Most patients, not much, but some patients, it's a problem. So most trials that have been done in the past use this 10-milligram dose. And what we learned at ASCO in 2019, our main meeting that we have once a year, was that people looked at a 5-milligram dose and had looked at 5 milligrams instead of the 10 milligrams. And what it showed is that the results seemed to be quite similar to what was seen with 10 milligrams. They did the study quite the same as what had been reported in the previous trial and the results looks similar. They didn't compare 5 milligrams versus 10 milligrams, which would've been nice because then we would have better information along that line. They did note that there was drowsiness that some patients had, and it looks similar to what was seen with the 10-milligram dose. But these data support, but don't prove, that giving 5 milligrams does look like it's good in this particular setting. So data from this year also supported that instead of giving the drug during the day when getting the chemotherapy, sometimes, people take it at bedtime, and there, the drowsiness is not as big a problem because you want to be drowsy at bedtime. So it's not proven that it works as well at bedtime, but it suggests that that actually is the case. Data from this year also supported that if you looked at those 3 drugs I mentioned before and just took out that 1 really, really expensive one, the NK1 receptor antagonist, and put the olanzapine in there instead, that very cheap medication, that that looked like that one with the olanzapine did better than the very expensive one. Not a whole lot better; they looked similar, but a little bit better in that setting, and it was a whole lot cheaper. This was also seen in a publication that came out a couple of years ago which showed the same sort of result. Again, not proof that it's beneficial, that it's okay to do that, but it looked better. So the next obvious question that comes up then is when you have these 4 drugs that you give, the 3 drugs I mentioned before and this fourth one, what about if you take away that more expensive one and see how they do there? So there was a trial at the ASCO meeting that suggested that the addition of that expensive medications didn't provide a whole lot more benefit. Right now, there is a trial going on across the United States, with about 800 patients who are scheduled to go on this trial, and it's approving about 30 patients a month, which is a pretty good accrual rate, which is looking at this particular question where people would get the 4-drug regimen versus 3 drugs where they take away the expensive intravenous medication. So, in summary, 35 to 40 years ago, when I started my cancer career, when I was about 10 years old, most patients had a lot a trouble with nausea and vomiting with drugs like Cisplatinum. Now, this a minority of patients who have a lot of problems, and we're continuing to find new things that will make things better along this line. Thank you for your attention. ASCO: Thank you Dr. Loprinzi. Learn more about these topics and other research presented at the 2019 ASCO Annual Meeting at www.cancer.net. If this podcast was useful, please take a minute to subscribe, rate, and review the show on Apple Podcasts or Google Play. And stay tuned for additional Research Round Up podcasts coming later this summer. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds breakthrough research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at conquer.org/support.

Inspiration and insight from breast cancer patients, with Dr. Gabriel Hortobagyi

Investigating Breast Cancer

Play Episode Listen Later Apr 12, 2019 40:45

At first glance, it would seem that any of us who follow the breast cancer experience would look to the investigators – the scientists, researchers and their teams – for inspiration. They are, after all, dedicating their lives to fighting cancer. In this conversation, you’ll hear the opposite. To listen to Dr. Gabriel Hortobagyi, you hear the inspiration and insight that he and his teams gain from the grace of breast cancer patients – in particular, people who have triple negative breast cancer and their families. You’ll also hear about the unique, novel research that Dr. Hortobagyi and his colleagues are doing to investigate resistance to various therapies and ways to develop combination therapy to overcome the resistance. This was a powerful, thoughtful, hopeful conversation with a scientist who knows, as he says, that the patient is the most important player on the team. More about Dr. Hortobagyi – he is a Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. He is also, not insignificantly, the Chair of the BCRF Scientific Advisory Board.

university professor inspiration breast cancer cancer patients texas md anderson cancer center breast medical oncology

Breast Cancer – Debu Tripathy, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018

OBR Peer-Spectives

Play Episode Listen Later Nov 2, 2018 11:42

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson, discuss IMpassion130, SOLAR-1 and other breast cancer clinical studies presented at the meeting

professor md solar clinical breast cancer cedars sinai medical center md anderson hematology oncology esmo debu breast medical oncology

S1 Ep.5: Breast Cancer and Lynch

Expert Approach to Hereditary Gastrointestinal Cancers presented by CGA-IGC

Play Episode Listen Later Oct 4, 2018 22:16

How to counsel patients about the link between Breast Cancer and Lynch Syndrome featuring Dr. Nadine Tung In this episode, Dr. Katherine A. Germansky interviews Dr. Nadine Tung, Director of Breast Medical Oncology and Director of Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center. She will be discussing the link between Lynch Syndrome and Breast Cancer. Hosted by: Katharine A. Germansky, MD Gastroenterologist at Beth Israel Deaconess Medical Center Note: This episode was recorded on 7/10/2018. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. The content reflects expert opinion at the time of recording.

director israel lynch breast cancer beth israel deaconess medical center prevention program lynch syndrome cancer genetics breast medical oncology

Encore: When Men Get Breast Cancer

Frankly Speaking About Cancer with the Cancer Support Community

Play Episode Listen Later Jun 20, 2017 58:59

Each year in the U.S., about 2,240 cases of breast cancer are diagnosed in men, compared to about 232,000 cases in women. Because men only represent 1% of the breast cancer diagnosis, we don't often hear about their cancer journey. With us today to inform and shed on light on male breast cancer are Dr. Oliver Bogler and Dr. Sharon Giordano. Dr. Bogler is Senior Vice President of Academic Affairs and Professor of Neurosurgery Research at MD Anderson. He also serves as its Vice President of the Global Academic Programs. Dr. Bogler was diagnosed with breast cancer in Sept. 2012. Dr. Sharon Giordano is a Board Certified Medical Oncologist. She is also a professor with tenure at the University of Texas M. D. Anderson Cancer Center in the Department of Breast Medical Oncology and Chair of the Department of Health Services Research.

university professor vice president senior vice president breast cancer academic affairs voiceamerica md anderson health services research cancer support community anderson cancer center breast medical oncology

Encore: When Men Get Breast Cancer

Frankly Speaking About Cancer with the Cancer Support Community

Play Episode Listen Later Oct 18, 2016 58:59

Each year in the U.S., about 2,240 cases of breast cancer are diagnosed in men, compared to about 232,000 cases in women. Because men only represent 1% of the breast cancer diagnosis, we don't often hear about their cancer journey. With us today to inform and shed on light on male breast cancer are Dr. Oliver Bogler and Dr. Sharon Giordano. Dr. Bogler is Senior Vice President of Academic Affairs and Professor of Neurosurgery Research at MD Anderson. He also serves as its Vice President of the Global Academic Programs. Dr. Bogler was diagnosed with breast cancer in Sept. 2012. Dr. Sharon Giordano is a Board Certified Medical Oncologist. She is also a professor with tenure at the University of Texas M. D. Anderson Cancer Center in the Department of Breast Medical Oncology and Chair of the Department of Health Services Research.

university professor vice president senior vice president breast cancer academic affairs voiceamerica md anderson health services research cancer support community anderson cancer center breast medical oncology

Special Encore Presentation: When Men Get Breast Cancer

Frankly Speaking About Cancer with the Cancer Support Community

Play Episode Listen Later Oct 20, 2015 58:59

Each year in the U.S., about 2,240 cases of breast cancer are diagnosed in men, compared to about 232,000 cases in women. Because men only represent 1% of the breast cancer diagnosis, we don't often hear about their cancer journey. With us today to inform and shed on light on male breast cancer are Dr. Oliver Bogler and Dr. Sharon Giordano. Dr. Bogler is Senior Vice President of Academic Affairs and Professor of Neurosurgery Research at MD Anderson. He also serves as its Vice President of the Global Academic Programs. Dr. Bogler was diagnosed with breast cancer in Sept. 2012. Dr. Sharon Giordano is a Board Certified Medical Oncologist. She is also a professor with tenure at the University of Texas M. D. Anderson Cancer Center in the Department of Breast Medical Oncology and Chair of the Department of Health Services Research.

university professor vice president senior vice president breast cancer academic affairs voiceamerica md anderson health services research special encore cancer support community special encore presentation anderson cancer center breast medical oncology

Unmet Needs in Breast Cancer Management: Where Can Integrative Medicine Make a Difference? - June 16, 2015

Integrative Medicine

Play Episode Listen Later Jun 18, 2015 56:28

Lecture Series - Integrative Medicine Program: Debu Tripathy, M.D., Professor of Medicine, Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

university professor management medicine tx breast cancer make a difference integrative medicine unmet needs texas md anderson cancer center breast medical oncology

When Men Get Breast Cancer

Frankly Speaking About Cancer with the Cancer Support Community

Play Episode Listen Later Jun 17, 2014 58:59

Each year in the U.S., about 2,240 cases of breast cancer are diagnosed in men, compared to about 232,000 cases in women. Because men only represent 1% of the breast cancer diagnosis, we don't often hear about their cancer journey. With us today to inform and shed on light on male breast cancer are Dr. Oliver Bogler and Dr. Sharon Giordano. Dr. Bogler is Senior Vice President of Academic Affairs and Professor of Neurosurgery Research at MD Anderson. He also serves as its Vice President of the Global Academic Programs. Dr. Bogler was diagnosed with breast cancer in Sept. 2012. Dr. Sharon Giordano is a Board Certified Medical Oncologist. She is also a professor with tenure at the University of Texas M. D. Anderson Cancer Center in the Department of Breast Medical Oncology and Chair of the Department of Health Services Research.

university professor vice president senior vice president breast cancer academic affairs voiceamerica md anderson health services research cancer support community anderson cancer center breast medical oncology

Breast and Ovarian Cancers Moon Shot update

cancer breast ovarian reproductive medicine gynecologic breast medical oncology

Play Episode Listen Later May 27, 2014 17:46

The moon shot for breast and ovarian cancer focuses on two diseases: triple-negative breast cancer and high-grade serous ovarian cancer. Jennifer Litton, M.D., associate professor of Breast Medical Oncology, and Shannon Westin, M.D., assistant professor of Gynecologic and Reproductive Medicine, discuss several new and exciting projects underway that can quickly make a difference in the detection and treatment of these cancers.

Cancer early detection – genetic testing

Play Episode Listen Later Mar 17, 2014 21:53

Breast cancer, ovarian cancer and colon cancer are the most common cancer types that are tested for an inherited mutation. Banu Arun, M.D., professor of Breast Medical Oncology; Karen Lu, M.D., professor and chair of Gynecologic Oncology and Reproductive Medicine; and Nancy You, M.D., assistant professor of Surgical Oncology and Affiliate Faculty; all part of MD Anderson Cancer Center’s Clinical Cancer Genetics Program, discuss the role of genetics in cancer.

cancer breast genetic testing early detection md anderson cancer center reproductive medicine surgical oncology gynecologic oncology affiliate faculty breast medical oncology nancy you

Young breast cancer patients with early-stage disease may undergo unnecessary testing when diagnosed

young testing disease breast cancer diagnosed unnecessary tm early stage cancer patients md anderson cancer center undergo health services research nmbs breast medical oncology

Play Episode Listen Later Dec 16, 2013 14:40

More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures – including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis. Carlos Barcenas, M.D., assistant professor, Breast Medical Oncology and Sharon Giordano, M.D., professor, Breast Medical Oncology and professor and chair of Health Services Research, at MD Anderson Cancer Center, discuss this study.

Breast cancer – most common cancer in women

women university breast cancer breast giordano texas md anderson cancer center health services research breast medical oncology

Play Episode Listen Later Dec 3, 2013 13:46

Breast cancer has two main types: ductal carcinoma and lobular carcinoma. These two types of breast cancer present and behave differently but they are treated the same way. Sharon Giordano, M.D., professor in Breast Medical Oncology at The University of Texas MD Anderson Cancer Center and chair of Health Services Research, discusses the differences between ductal and lobular carcinomas including in situ (noninvasive) cases. Giordano explains self-examination, diagnosis, treatment, screening recommendations and research in breast cancer.

Hereditary Breast and Ovarian Cancer Course Syndrome: Management of Breast Cancer Risk

Hereditary Breast and Ovarian Cancer syndrome (HBOC)

Play Episode Listen Later Dec 4, 2012 19:04

Most women have a 10-11% lifetime risk of developing breast cancer by age 70. However, women with a BRCA1 or BRCA2 mutation have up to an 80% risk of developing breast cancer in their lifetime. Dr. Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center, says that’s why it’s important to evaluate family history carefully. In this lecture, Dr. Arun discusses breast cancer risk management options, including screening, chemoprevention, and surgery, for patients with a BRCA1 or BRCA2 mutation.

university professor management syndrome breast cancer co director hereditary ovarian cancer cancer risk brca1 brca2 texas md anderson cancer center breast medical oncology clinical cancer genetics

Hereditary Breast and Ovarian Cancer Course Syndrome: Management of Breast Cancer Risk

Hereditary Breast and Ovarian Cancer syndrome (HBOC)

Play Episode Listen Later Dec 4, 2012 19:04

Most women have a 10-11% lifetime risk of developing breast cancer by age 70. However, women with a BRCA1 or BRCA2 mutation have up to an 80% risk of developing breast cancer in their lifetime. Dr. Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at The University of Texas MD Anderson Cancer Center, says that’s why it’s important to evaluate family history carefully. In this lecture, Dr. Arun discusses breast cancer risk management options, including screening, chemoprevention, and surgery, for patients with a BRCA1 or BRCA2 mutation.

university professor management syndrome breast cancer co director hereditary ovarian cancer cancer risk brca1 brca2 texas md anderson cancer center breast medical oncology clinical cancer genetics

Breast Cancer and Pregnancy

Hereditary Breast and Ovarian Cancer syndrome (HBOC)

Play Episode Listen Later Dec 4, 2012 23:09

Breast cancer is the most common cancer in pregnant women and tends to affect women in their mid-30s. Dr. Jennifer Litton, Assistant Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, says that “approximately 1 in 3,000 to 3 in 10,000 deliveries occur in women who’ve also been diagnosed with breast cancer.” Additionally, women who have a known BRCA1 or BRCA2 gene mutation tend to develop breast cancer at an earlier age, which means that these women are more likely to develop breast cancer during their childbearing years. In this lecture, Dr. Litton outlines the epidemiology of breast cancer during pregnancy, diagnosis, staging, locoregional therapy, and systemic therapy, and she discusses outcomes in the children born to women who had chemotherapy during their pregnancy.

university pregnancy assistant professor breast cancer breast brca1 brca2 texas md anderson cancer center litton breast medical oncology

Breast Cancer and Pregnancy

Hereditary Breast and Ovarian Cancer syndrome (HBOC)

Play Episode Listen Later Dec 4, 2012 23:08

Breast cancer is the most common cancer in pregnant women and tends to affect women in their mid-30s. Dr. Jennifer Litton, Assistant Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, says that “approximately 1 in 3,000 to 3 in 10,000 deliveries occur in women who’ve also been diagnosed with breast cancer.” Additionally, women who have a known BRCA1 or BRCA2 gene mutation tend to develop breast cancer at an earlier age, which means that these women are more likely to develop breast cancer during their childbearing years. In this lecture, Dr. Litton outlines the epidemiology of breast cancer during pregnancy, diagnosis, staging, locoregional therapy, and systemic therapy, and she discusses outcomes in the children born to women who had chemotherapy during their pregnancy.

university pregnancy assistant professor breast cancer breast brca1 brca2 texas md anderson cancer center litton breast medical oncology

Breast Cancer, Pregnancy and Fertility

Hereditary Breast and Ovarian Cancer syndrome (HBOC)

Play Episode Listen Later Dec 4, 2012 22:40

Pregnancy and future pregnancies after a breast cancer diagnosis are a significant concern for survivors. There are several key studies addressing this issue. Dr. Jennifer Litton, Assistant Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, says the good news is that “women who develop breast cancer do not show an increased risk of dying of breast cancer if they go on to have a future pregnancy.” In her lecture, “Breast Cancer, Pregnancy, and Fertility,” Dr. Litton discusses available information regarding pregnancies after breast cancer and advises how long a woman should wait after diagnosis before trying to become pregnant.

university pregnancy assistant professor fertility breast cancer texas md anderson cancer center litton breast medical oncology

Breast Cancer, Pregnancy and Fertility

Hereditary Breast and Ovarian Cancer syndrome (HBOC)

Play Episode Listen Later Dec 4, 2012 22:40

Pregnancy and future pregnancies after a breast cancer diagnosis are a significant concern for survivors. There are several key studies addressing this issue. Dr. Jennifer Litton, Assistant Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, says the good news is that “women who develop breast cancer do not show an increased risk of dying of breast cancer if they go on to have a future pregnancy.” In her lecture, “Breast Cancer, Pregnancy, and Fertility,” Dr. Litton discusses available information regarding pregnancies after breast cancer and advises how long a woman should wait after diagnosis before trying to become pregnant.

university pregnancy assistant professor fertility breast cancer texas md anderson cancer center litton breast medical oncology

Breast Cancer Survivorship

Cancer Survivorship 1

Play Episode Listen Later Nov 28, 2012 21:05

In her lecture, "Breast Cancer Survivorship," Dr. P. K. Morrow, Assistant Professor of Breast Medical Oncology and Associate Medical Director for Breast Cancer Survivorship at The University of Texas MD Anderson Cancer Center, discusses recommendations and guidelines for the assessment and management of long-term complications from breast cancer and its treatments.

university assistant professor breast cancer morrow cancer survivorship associate medical director texas md anderson cancer center breast medical oncology

Breast Cancer Survivorship

Cancer Survivorship 1

Play Episode Listen Later Nov 28, 2012 21:06

In her lecture, "Breast Cancer Survivorship," Dr. P. K. Morrow, Assistant Professor of Breast Medical Oncology and Associate Medical Director for Breast Cancer Survivorship at The University of Texas MD Anderson Cancer Center, discusses recommendations and guidelines for the assessment and management of long-term complications from breast cancer and its treatments.

university assistant professor breast cancer morrow cancer survivorship associate medical director texas md anderson cancer center breast medical oncology

Common Sites of Metastasis

ms rn sites brice metastasis breast medical oncology

Play Episode Listen Later Nov 21, 2012 11:12

Bonnie M. Brice, MS, RN, ANP-C, AOCNP, Advanced Practice Nurse, Breast Medical Oncology

Inflammatory Breast Cancer: Need for a Multidisciplinary Approach to Provide the Best Cancer Treatment

professor executive director clinic cancer treatment multidisciplinary ueno inflammatory breast cancer breast medical oncology

Play Episode Listen Later Nov 21, 2012 21:55

Naoto T. Ueno, M.D., Ph.D., Professor, Breast Medical Oncology, Section Chieft, Translational Breast Cancer Research, Executive Director of the Morgan Welch IBC Research Program and Clinic

Breast Cancer Survivorship

assistant professor breast cancer morrow cancer survivorship breast medical oncology

Play Episode Listen Later Nov 21, 2012 21:05

P. K. Morrow, M.D., Assistant Professor, Department of Breast Medical Oncology

Breast Cancer Survivorship

assistant professor breast cancer morrow cancer survivorship breast medical oncology

Play Episode Listen Later Nov 21, 2012 21:05

P. K. Morrow, M.D., Assistant Professor, Department of Breast Medical Oncology

Risk Assessment and Management of High Risk Women

Play Episode Listen Later Nov 21, 2012 24:45

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director for Clinical Cancer Genetics

women professor management high risk risk assessment co medical director breast medical oncology clinical cancer genetics

Biological Features of Inflammatory Breast Cancer

adjunct professor biological inflammatory breast cancer breast medical oncology

Play Episode Listen Later Nov 21, 2012 29:52

Massimo Cristofanilli, M.D., Adjunct Professor, Department of Breast Medical Oncology

Biological Features of Inflammatory Breast Cancer

adjunct professor biological inflammatory breast cancer breast medical oncology

Play Episode Listen Later Nov 21, 2012 29:52

Massimo Cristofanilli, M.D., Adjunct Professor, Department of Breast Medical Oncology

Inflammatory Breast Cancer: Need for a Multidisciplinary Approach to Provide the Best Cancer Treatment

professor executive director clinic cancer treatment multidisciplinary ueno inflammatory breast cancer breast medical oncology

Play Episode Listen Later Nov 21, 2012 21:55

Naoto T. Ueno, M.D., Ph.D., Professor, Breast Medical Oncology, Section Chieft, Translational Breast Cancer Research, Executive Director of the Morgan Welch IBC Research Program and Clinic

Risk Assessment and Management of High Risk Women

Play Episode Listen Later Nov 21, 2012 24:45

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director for Clinical Cancer Genetics

women professor management high risk risk assessment co medical director breast medical oncology clinical cancer genetics

Identification of High-risk Patients and Genetic Testing

Play Episode Listen Later Nov 21, 2012 16:05

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director, Clinical Cancer Genetics

professor patients identification high risk genetic testing co medical director breast medical oncology clinical cancer genetics

Identification of High-risk Patients and Genetic Testing

Play Episode Listen Later Nov 21, 2012 16:03

Banu Arun, M.D., Professor, Department of Breast Medical Oncology, Co-Medical Director, Clinical Cancer Genetics

professor patients identification high risk genetic testing co medical director breast medical oncology clinical cancer genetics

Surveillance after Treatment

treatments rn surveillance msn breast medical oncology

Play Episode Listen Later Nov 21, 2012 19:28

Christi Bowe, MSN, RN, ANP-C, ACONP, Advanced Practice Nurse, Breast Medical Oncology

Surveillance after Treatment

treatments rn surveillance msn breast medical oncology

Play Episode Listen Later Nov 21, 2012 19:26

Christi Bowe, MSN, RN, ANP-C, ACONP, Advanced Practice Nurse, Breast Medical Oncology

Common Sites of Metastasis

ms rn sites brice metastasis breast medical oncology

Play Episode Listen Later Nov 21, 2012 11:05

Bonnie M. Brice, MS, RN, ANP-C, AOCNP, Advanced Practice Nurse, Breast Medical Oncology

Staging

rn msn staging michelle o anp bc breast medical oncology

Play Episode Listen Later Nov 21, 2012 17:40

Michelle O. Butaud, MSN, RN, ANP-BC, AOCNP, Advanced Practice Nurse, Breast Medical Oncology

Staging